Skip to main content
. Author manuscript; available in PMC: 2019 Mar 13.
Published in final edited form as: Biol Psychiatry. 2017 Nov 6;84(7):488–498. doi: 10.1016/j.biopsych.2017.10.023

Figure 1.

Figure 1.

Experimental Design. (A) Peripherally-administered (−)-P7C3-S243 achieves blood levels in rats equivalent to that required for biological activity in mouse preclinical models, and (B) also enhances hippocampal neurogenesis in TgF344-AD rats. BrdU positive cell counts treatment effect was t=3.763, df=10, p=0.0037 using a two-tailed Student’s t-test. Once this effect was established, we proceeded to evaluate the efficacy of (−)-P7C3-S243 in TgF344-AD rats using the experimental design in panel (C). Beginning at 6 months of age, (−)-P7C3-S243 at 10 mg/kg was administered daily to male and female TgF344-AD rats and age/sex-matched WT littermates. Behavior was assessed at 15 and 24 months, following 9 and 18 months of (−)-P7C3-S243 or vehicle treatment, respectively, in the form of locomotor activity (open field), hippocampal-dependent spatial learning and memory (Barnes maze and Morris water maze), and depression-like behavior (Porsolt forced swim task). Pathological and biochemical analysis was subsequently conducted on tissue collected at both time points.